MEF2A and neoplasm: A past study showed that miRNA could enhance the mitochondrial function and activate OXPHOS by downregulating MEF2A [61], while tumor-related genes enhance OXPHOS through metabolic reprogramming to inhibit sensitivity to TKI drugs [62].